FILING ANALYSIS · THURSDAY, NOVEMBER 5
REVELATION BIOSCIENCES, INC. REVB — 8-K: Results of Operations and Financial Condition
neutral
The company reported a net loss of $3.3 million for the three months ended September 30, 2026, and $9.6 million for the nine months ended September 30, 2026, with cash and cash equivalents of $9.1 million, which is expected to fund operations into the second quarter of 2027. No significant quantified surprises were disclosed in the filing.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →